Quality standards are sets of concise statements designed to help health care professionals easily and quickly know what care to provide, based on the best evidence. 
See below for the quality statements and click for more detail.
Quality Statement 1: Identifying  and Diagnosing Opioid Use Disorder 
People at risk of opioid use disorder are asked about their  opioid use and are further assessed as appropriate. 
Quality Statement 2: Comprehensive Assessment and  Collaborative Care Plan 
People diagnosed with or identified as having opioid use  disorder have a comprehensive assessment and a care plan developed in  collaboration with their care providers.
Quality Statement 3: Addressing Physical Health, Mental  Health, Additional Addiction Treatment Needs, and Social Needs
People with opioid use disorder have integrated, concurrent,  culturally safe management of their physical health, mental health, additional  addiction treatment needs, and social needs.
Quality Statement 4: Information to Participate in Care
People with opioid use disorder are provided with  information to enable them to participate in their care. If their family is  involved, they are also provided with this information.
Quality Statement 5: Opioid Agonist Therapy as First-Line  Treatment
People with opioid use disorder are informed that treatment  that includes opioid agonist therapy is safer and more effective than  treatments that do not include opioid agonist therapy.
Quality Statement 6: Access to Opioid Agonist Therapy
People diagnosed with or identified as having opioid use  disorder have access to opioid agonist therapy as soon as possible, within a  maximum of 3 days.
Quality Statement 7: Treatment of Opioid Withdrawal Symptoms
People with opioid use disorder who are in moderate or  severe withdrawal from opioids are offered relief of their symptoms with  buprenorphine/naloxone within 2 hours.
Quality Statement 8: Access to Take-Home Naloxone and to  Overdose Education
People with opioid use disorder and their families have  immediate access to take-home naloxone and to overdose education.
Quality Statement 9: Tapering Off of Opioid Agonist Therapy
People who have achieved sustained stability on opioid  agonist therapy who wish to taper off are supported in a collaborative slow  taper if clinically appropriate.
Quality Statement 10: Concurrent Mental Health Disorders
People with opioid use disorder who also have a mental  health disorder are offered concurrent treatment for their mental health  disorder.
Quality Statement 11: Harm Reduction
People who use opioids have same-day access to harm  reduction services. A comprehensive harm reduction approach includes education,  safe supplies, infectious disease testing, vaccinations, appropriate referrals,  and supervised consumption services.